Teleflex has announced that its Semprus BioSciences subsidiary has received FDA clearance for a vascular access catheter, according to a news release.
The Nylus peripherally inserted central catheter is indicated to provide peripheral access to the central venous system for infusion, intravenous therapy, blood sampling, central venous pressure monitoring and power injection of contrast media.
"Teleflex is pleased to obtain FDA clearance for the Nylus PICC, which is the first generation of the Semprus Sustain platform technology to move through the FDA 510(k) process," said Benson Smith, chairman, president and CEO of Teleflex, in the release. "We continue to be excited about the technology's potential to reduce thrombus-related complications for patients in a variety of applications."
FDA clearance follows the product's European market clearance in July.
Teleflex is headquartered in Limerick, Pa.
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.